Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

Consulting or Advisory Role: Novartis, Pfizer, Merck, Lilly, AstraZeneca, Genentech, Eisai, Sanofi, Bristol Myers Squibb, Seagen, Daiichi Sankyo, Immunomedics/Gilead Sciences, Inc., Zymeworks, ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and ...

Pfizer Inc. (NYSE:PFE) intends to present the data to regulatory bodies in order to start the regulatory filing process for HYMPAVZI in hemophilia patients with inhibitors.